Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

PAREXEL's Acquisition By Pamplona Approved By Shareholders

Published 09/26/2017, 10:51 PM
Updated 07/09/2023, 06:31 AM

PAREXEL International Corporation (NASDAQ:PRXL) is again in the news following the receipt of shareholders’ approval for the impending sell-off of the company to certain investment funds associated with Pamplona Capital Management. The transaction is expected to be completed by Sep 29 following which the company will turn into a privately-held organization

Per the terms of this approximately $5-billion worth deal, Pamplona is slated to acquire all of PAREXEL’s outstanding shares for $88.10 a share in cash. According to the company, the offer price by Pamplona was attractively placed at a premium of 27.9% to the stock’s price just before the market speculation of the news which took place on May 5. Hence 98% of shareholders’ votes were casted in favor of the deal. Notably, the company received the acquisition approval after a shareholders meeting held on Sep 15.

PARAXEL also seems to be upbeat about this sell-off. Per management, the deal will help the company solidify its footprint to exploit opportunities in the pharmaceutical and healthcare spaces.

This leading biopharmaceutical services provider delivered encouraging performance in fiscal 2017. Moreover, the company has an attractive track record of growing organically as well as through acquisitions. In this regard, the company recently introduced a new end-to-end service offering intended to deliver real-world data insights to aid life science companies in enhancing product value demonstration under its PARAXEL Access unit.

PARAXEL operates in a highly fragmented medical services space with the presence of certain well-established players like Medpace Holdings, Inc. (NASDAQ:MEDP) , BioTelemetry, Inc. (NASDAQ:BEAT) and CareDx, Inc. (NASDAQ:CDNA) .

4 Stocks to Watch after the Massive Equifax (NYSE:EFX) Hack

Cybersecurity stocks spiked on recent news of a data breach affecting 143 million Americans. But which stocks are the best buy candidates right now? And what does the future hold for the cybersecurity industry?

Equifax is just the most recent victim. Computer hacking and identity theft are more common than ever. Zacks has just released Cybersecurity! An Investor’s Guide to inform Zacks.com readers about this $170 billion/year space. More importantly, it highlights 4 cybersecurity picks with strong profit potential.

Get the new Investing Guide now>>



BioTelemetry, Inc. (BEAT): Free Stock Analysis Report

PAREXEL International Corporation (PRXL): Free Stock Analysis Report

CareDx, Inc. (CDNA): Free Stock Analysis Report

Medpace Holdings, Inc. (MEDP): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.